JW (Cayman) Therapeutics Co. Ltd
2126
Rank in Stocks
#19002
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company... JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Share Price
$0.27150273
Last synced: 2026-11-19
Market Cap
$113.11M
Change (1 day)
-10.12%
Change (1 year)
-34.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade JW (Cayman) Therapeutics Co. Ltd (2126)
Category
Healthcare
Operating Margin for JW (Cayman) Therapeutics Co. Ltd (2126)
Operating Margin as of November 2026 TTM: -95.03%
According to JW (Cayman) Therapeutics Co. Ltd's latest financial reports, its current operating margin (TTM) is -95.03%. At the end of 2025 the company had an operating margin of -87.48%.
Operating Margin history for JW (Cayman) Therapeutics Co. Ltd from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -95.03% | 8.63% |
| 2025 | -87.48% | -69.86% |
| 2024 | -290.28% | -36.09% |
| 2023 | -454.17% | -22.68% |
| 2022 | -587.42% | -76.17% |
| 2021 | -2,464.80% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -3,711.76% | -92.89% |
| 2018 | -52,200.93% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -97.94% |
US
|
|
| 33.87% | -100.36% |
US
|
|
| -116.04% | -98.78% |
US
|
|
| 25.57% | -100.27% |
AU
|
|
| 31.23% | -100.33% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about JW (Cayman) Therapeutics Co. Ltd's operating margin
What is JW (Cayman) Therapeutics Co. Ltd's operating margin?
JW (Cayman) Therapeutics Co. Ltd's operating margin is -95.03%, as of Nov 2026.
What was JW (Cayman) Therapeutics Co. Ltd's operating margin in 2025?
In 2025, JW (Cayman) Therapeutics Co. Ltd's operating margin was -87.48%, compared with -290.28% in 2024.
How has JW (Cayman) Therapeutics Co. Ltd's operating margin changed since 2020?
From 2020 to 2025, JW (Cayman) Therapeutics Co. Ltd's operating margin was highest in 2020 (0.00%) and lowest in 2021 (-2,464.80%).
How does JW (Cayman) Therapeutics Co. Ltd's operating margin compare with similar companies?
JW (Cayman) Therapeutics Co. Ltd's operating margin (-95.03%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.